GlassScriptPhysician profile
Joni S Smith
NPI 1639525934
$13,908.66
in general payments reported to CMS, 2019-2025
35 companies · $3,602 in 2025
The $3,602 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,971 · 2022: $1,954 · 2023: $2,971 · 2024: $3,411 · 2025: $3,602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,909 · Education: $75.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,908.97 |
| Education | $75.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,162.48 | 2021-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $2,269.80 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $1,928.10 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,132.76 | 2021-2025 | Dupixent |
| Optinose US, INC. | $726.63 | 2021-2025 | |
| Biocryst US Sales Co., LLC | $673.62 | 2021-2025 | Orladeyo |
| Csl Behring | $589.13 | 2021-2025 | Haegarda, Andembry |
| Pfizer INC. | $463.93 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $407.32 | 2021-2025 | |
| Leo Pharma INC. | $313.69 | 2022-2025 | Adbry |
| Pharming Healthcare, INC. | $284.18 | 2021-2025 | Ruconest |
| Phathom Pharmaceuticals, INC. | $255.60 | 2024-2025 | Voquezna |
| Abbvie INC. | $244.39 | 2021-2022 | |
| Grifols USA, LLC | $188.77 | 2021-2025 | Xembify |
| Kaleo, INC. | $132.72 | 2021-2023 | Auvi-Q |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $132.58 | 2021-2025 | Takhzyro, Cuvitru |
| Hikma Pharmaceuticals USA | $114.36 | 2022-2025 | Ryaltris |
| Incyte Corporation | $104.37 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $79.12 | 2024-2025 | Ebglyss |
| Ionis Pharmaceuticals, INC. | $74.72 | 2025 | Dawnzera |
| Genentech USA, INC. | $72.33 | 2021-2025 | Xolair |
| Cycle Pharmaceuticals INC | $70.99 | 2025 | Sajazir |
| Galderma Laboratories, L.P. | $66.55 | 2025 | Nemluvio |
| Amgen INC. | $66.36 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $65.37 | 2023 | |
| Ars Pharmaceuticals Operations, INC. | $58.28 | 2025 | Neffy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.86 | 2021 | |
| Dermavant Sciences, INC. | $41.61 | 2024 | Vtama |
| Organon LLC | $30.53 | 2025 | Vtama |
| Adma Biomanufacturing LLC | $26.89 | 2021 | |
| Uswm, LLC | $21.00 | 2021 | |
| Mylan Specialty L.P. | $19.75 | 2022 | |
| Aimmune Therapeutics, INC. | $18.61 | 2022 | |
| Merck Sharp & Dohme LLC | $13.01 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $11.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joni Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.